Systematic review shows Vi-TT vaccine significantly reduces typhoid risk in children and adolescents, suggesting high immunogenicity and manageable safety concerns.
Typhoid fever is a major cause of morbidity and mortality in developing countries. This review assessed the efficacy, safety, and immunogenicity of the tetanus toxoid conjugate typhoid vaccine (Vi-TT) in children and adolescents. Randomized controlled trials involving Vi-TT in individuals under 18 were included. Eligible studies were screened, and quality was assessed using the Cochrane Risk of Bias-2 tool. Meta-analysis was conducted with RevMan Web. Four trials with 111 481 children found the risk of blood culture-confirmed typhoid fever after Vi-TT to be 0.18 (95% CI [0.13, 0.24]) compared with nontyphoid vaccines. Adverse event rates were similar, with a serious adverse event risk of 0.82 (95% CI [0.71, 0.95]) within six months. Seroconversion was 58.04 times higher at 28 days and 21.80 times higher after 18 months postvaccination (95% CIs [36.24, 92.96] and [15.44, 30.80], respectively). One trial had a high risk of bias, so sensitivity analysis was performed with and without it. GRADE assessment showed strong evidence that Vi-TT reduces typhoid risk without significant safety concerns. Seroconversion declined over time but remained significantly higher after 18 months. This concludes that Vi-TT is safe and effective for children and adolescents, and is recommended for vaccination in endemic areas.
No takes yet. Share an insight, caveat, or question.
Gyawali et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: